Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3411-3420 Newer>

The Motley Fool January 16, 2007 Brian Lawler	MedImmune's Improved Flu Vaccine One of the three most important traits for a drug's success is convenience in dosing, so investors should be mindful of the FDA's actions on FluMist, MedImmune's nasal spray vaccine, in the coming months.
BusinessWeek January 22, 2007 Arlene Weintraub	Open-Heart Nightmare "Coronary: A True Story of Medicine Gone Awry" casts a beacon on the all-too-frequent association of medicine and the pursuit of profit.
InternetNews January 12, 2007 Michael Hickins	Health IT Joins The 21st Century Employers, as well as state and federal agencies, are pushing a variety of IT-based initiatives that may well begin having tangible effects within five years in the health care industry.
The Motley Fool January 12, 2007 Brian Lawler	What's Next for Northfield Labs? When Northfield released results from its phase 3 trial for PolyHeme, its shares fell almost 60% in one day. But Northfield again said it's not giving up on PolyHeme and would eventually apply to the FDA to market the drug.
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool January 10, 2007 Brian Lawler	Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result.
The Motley Fool January 9, 2007 Brian Lawler	ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation.
Pharmaceutical Executive January 1, 2007 Davenport et al.	Sales Slip Even before Pfizer blinked, companies were asking, "What ails sales?" In this annual survey, 50-plus pharmas and biotechs answer the hard questions about reps' productivity, profitability, and what to do about it.
Pharmaceutical Executive January 1, 2007 Jill Wechsler	Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007.
<Older 3411-3420 Newer> Return to current articles.